Regenicin, Inc. (RGIN)
Regenicin, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Little Falls, NJ, US. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $15,348. On trailing twelve-month figures it carries a trailing P/E of -0.02, a net margin of 0.0%. Its beta of -2.27 implies it has historically moved less than the broad market.
Regenicin, Inc. is dedicated to the development and commercialization of advanced tissue-engineered skin replacement technologies. Its product line features NovaDerm, a sophisticated multi-layered living and cultured skin substitute engineered for treating burn injuries, alongside TempaDerm, which addresses more localized wound areas like ulcers. These innovative solutions aim to rejuvenate the characteristics of healthy human skin, finding application in burn therapy, chronic wound management, and various plastic surgery procedures. Incorporated in 2007 and based in Little Falls, New Jersey, the company was previously known as Windstar, Inc., adopting the Regenicin, Inc. name in July 2010.
Regenicin, Inc. is most often compared with the following Healthcare names: